Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA
Sun Pharmaceutical Industries — Ranbaxy Laboratories — Q1 FY2015 Earnings Presentation
15 slides from Sun Pharmaceutical Industries's earnings presentation, Jul 29, 2014
Slide 1: Financial Results: April – June 2014 (Q1)
Ranbaxy Laboratories Limited FINANCIAL RESULTS: April – June 2014 (Q1) ARUN SAWHNEY CEO & MD Dept. 29 July Name 2014 Post Results Conference Call Privileged and Confidential
Slide 2: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “p
Slide 3: Key Achievements for Quarter 1, FY15
Key Achievements for Quarter 1, FY15 Financial Sales lower primarily due to the impact of voluntary suspension in API shipments Margin improvement continued during the Quarter 25,839 10% 23,722 8% Percent Rs. Mn Q1 FY14 Q1 FY15 Q1 FY14 Q1 FY15 Sales EBITDA/ Sales % Growth calculated on Constant
Slide 4: Other Areas
Other Areas Research & Development and Regulatory DF filings: 60; DF approvals:43 Derivatives Position Exposure down to ~$470 Mn as on 30 Jun 2014 from ~$568 Mn on 31st Mar 2014. Maturity: ~$33 Mn/month Debt Debt $1,060 Mn; Cash & Bank $214 Mn Net Debt $846 Mn Privileged and Confidential 4
Slide 5: Financial Performance
Ranbaxy Laboratories Limited Financial Performance FINANCIAL RESULTS: April – June 2014 (Q1) Dept. Name Privileged and Confidential
Slide 6: Sales Performance
Sales Performance Rs. Mn Consolidated Sales Q1 FY15 25,839 23,722 (12%) Q1 FY14 Q1 FY15 Sales grew in the major markets of India, West Europe and Russia Growth calculated on Constant Forex 6 Privileged and Confidential
Slide 7: North America
North America Rs. Mn Major markets -USA -Canada 8,023 7,617 (11%) Q1 FY14 Q1 FY15 Absorica™ growth continued during the Quarter Loss in Market Share of Amlo + Atorva Growth calculated on Constant Forex 7 Privileged and Confidential
Slide 8: India
India Rs. Mn 6,075 5,426 12% Q1 FY14 Q1 FY15 IPM stabilized after changes in pricing policy Primary sales recovered in the home market Growth calculated on Constant Forex 8 Privileged and Confidential
Slide 9: East Europe & CIS
East Europe & CIS Rs. Mn Major markets -Romania -Russia -Ukraine 3,260 3,388 (0%) Q1 FY14 Q1 FY15 Sales in Russia continued to grow Leadership position in Represented markets Growth calculated on Constant Forex 9 Privileged and Confidential
Slide 10: West Europe
West Europe Rs. Mn Major markets -France -Germany -UK 2,434 1,958 10% Q1 FY14 Q1 FY15 Sales in the region was helped by strong performance in UK Regional focus on profitability Growth calculated on Constant Forex 10 Privileged and Confidential
Slide 11: Asia Pacific & Latin America
Asia Pacific & Latin America Rs. Mn Major markets -ANZ -Malaysia 2,041 -Brazil 1,555 (26%) Q1 FY14 Q1 FY15 Sales impacted due to loss of tenders in Malaysia & lower demand and manufacturing delays in Australia. LATAM: Supply concerns impacted sales Growth calculated on Constant Forex 11 Privileg
Slide 12: Africa & Middle East
Africa & Middle East Rs. Mn Major markets -South Africa -Nigeria 2,828 2,149 (26%) Q1 FY14 Q1 FY15 Sales impacted by lower tender sales in the Quarter Growth calculated on Constant Forex 12 Privileged and Confidential
Slide 13: API & Others
API & Others Rs. Mn 2,263 466 (81%) Q1 FY14 Q1 FY15 Sales impacted by voluntary halt of shipments from Dewas and Toansa Growth calculated on Constant Forex 13 Privileged and Confidential
Slide 14: Financials Q1 FY15: INR (Mn)
Financials Q1 FY15: INR (Mn) Q1 FY2014 Particulars Q1 FY2015 5,561 -Within India 6,216 20,278 -Outside India 17,506 25,839 Sales 23,722 502 Other operating income 540 26,342 Total Operating Income 24,263 5,637 Total Material Consumption 4,599 5,131 Employee cost 5,286 4,135 Purchases of stock-in-tra
Slide 15: Questions & Answers
Questions & Answers Dept. Name Privileged and Confidential
Ranbaxy Laboratories — Q1 FY2015 Earnings Presentation on 6ix